News coverage about Egalet Corporation (NASDAQ:EGLT) has been trending somewhat positive recently, according to Accern. The research firm rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Egalet Corporation earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave news articles about the specialty pharmaceutical company an impact score of 46.2082007642109 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news headlines that may have effected Accern’s analysis:
- Brokers Issue Forecasts for Egalet Corporation’s FY2017 Earnings (EGLT) (americanbankingnews.com)
- Egalet Corporation (EGLT) Expected to Earn FY2017 Earnings of ($2.89) Per Share (americanbankingnews.com)
- Egalet Corp. :EGLT-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017 (finance.yahoo.com)
- ETFs with exposure to Egalet Corp. : November 9, 2017 (finance.yahoo.com)
- Brokerages Anticipate Egalet Corporation (EGLT) Will Announce Quarterly Sales of $8.51 Million (americanbankingnews.com)
Egalet Corporation (NASDAQ EGLT) remained flat at $$0.86 during trading hours on Tuesday. The company’s stock had a trading volume of 372,200 shares, compared to its average volume of 592,571. The company has a debt-to-equity ratio of -3.43, a quick ratio of 2.68 and a current ratio of 2.73. Egalet Corporation has a 52 week low of $0.85 and a 52 week high of $10.00.
EGLT has been the subject of a number of analyst reports. Gabelli downgraded shares of Egalet Corporation from a “buy” rating to a “hold” rating in a research note on Thursday, November 9th. Cantor Fitzgerald reissued an “overweight” rating on shares of Egalet Corporation in a research note on Sunday, August 20th. Stifel Nicolaus reissued a “buy” rating and issued a $6.00 price target (down from $14.00) on shares of Egalet Corporation in a research note on Thursday, August 10th. Finally, Guggenheim set a $7.00 price target on shares of Egalet Corporation and gave the stock a “buy” rating in a research note on Monday, August 14th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. Egalet Corporation presently has an average rating of “Buy” and a consensus target price of $7.10.
ILLEGAL ACTIVITY WARNING: “Egalet Corporation (EGLT) Earns Media Sentiment Rating of 0.11” was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.chaffeybreeze.com/2017/11/14/egalet-corporation-eglt-earns-media-sentiment-rating-of-0-11.html.
Egalet Corporation Company Profile
Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology.
Receive News & Ratings for Egalet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Egalet Corporation and related companies with MarketBeat.com's FREE daily email newsletter.